FDA Approves OLANZAPINE — Macleods Pharmaceuticals Limited
Macleods Pharmaceuticals has received approval from the U.S. Food and Drug Administration for its abbreviated new drug application, #ANDA202862, to manufacture and market olanzapine oral tablets. This move is expected to introduce a generic competitor into the antipsychotic market, potentially driving down prices and increasing competition for the established brand.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed